health pharma news today obesity drugs glp-1 today Drugmaker Eli Lilly announced that the FDA approved its daily pill, which will be marketed under the name Foundayo, to treat obesity. ABC News' Youri Benadjaoud reports What Really Happens When You

Please dont rely only on what you read here when making decisions about using a product, especially if you have any medical conditions, are pregnant, or breastfeeding

Ein zentrales Ergebnis der bisherigen Studien ist die Fhigkeit von BPC 157, die Angiogenese also die Bildung neuer Blutgefe zu frdern

Other side effects Additional reported side effects include: Joint pain and water retention Muscle and joint aches Headaches and nausea Receptor desensitization with prolonged use Potential suppression of natural GH and IGF-1 production Who should avoid IGF-1 LR3 Certain groups should not use IGF-1 LR3: Anyone with active cancer or tumor history Those with severe insulin resistance or diabetes Pregnant or nursing women Anyone under 25 whose growth plates haven't closed Those with existing hormonal imbalances IGF-1 LR3 is not FDA-approved for general medical use and remains primarily a research compound

These are typically transient